Article detail · 2024
Intrathecal Tigecycline in the Treatment of Hospital-Acquired Meningitis: A Review of Four Cases
- Year
- 2024
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue Surgical Infections
- Catalog match (ISSN) Surgical Infections
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
OpenAlex · English
Objectives:Carbapenem-resistant A. baumannii is a common cause of nosocomial meningitis, and it presents a challenge in terms of treatment because of limited therapeutic options. Intravenous tigecycline has been considered a potential salvage therapy against multi-drug–resistant Acinetobacter baumannii. However, its effectiveness is limited by its poor ability to cross the blood–brain barrier. As an alternative treatment option, intrathecal tigecycline has shown promise with its minimal side effects and high concentration in cerebrospinal fluid. Methods:In this report, we present a series of four cases infected with multi-drug–resistant A. baumannii following neurosurgery and treated with intrathecal tigecycline, including antimicrobial therapy. Results:The rate of successful microbiological response was 2 out of 3 cases (66%) in whom microbiological response could be tested anytime during the intrathecal therapy, whereas the 30-day survival rate after treatment completion was ¼ (25%). Conclusion:Although intrathecal tigecycline treatment has shown relative efficacy in achieving microbiological response, its impact on overall survival is still uncertain. Further studies involving larger groups of patients are necessary to evaluate the outcomes of intrathecal tigecycline therapy.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
3 citations
OpenAlex cited_by_count (cache / database)